siRNA therapy in cutaneous T-cell lymphoma cells using polymeric carriers

Area of Science:

• Biomaterials Science
• Molecular Biology
• Oncology

Background:

• Cutaneous T-cell lymphomas (CTCLs) are driven by molecular aberrations causing uncontrolled cell proliferation.
• RNA interference (RNAi) using short interfering RNAs (siRNAs) offers a potential therapeutic strategy for CTCL.
• Effective intracellular delivery of siRNAs requires functional biomaterial carriers.

Purpose of the Study:

• To evaluate lipid-substituted polyethylenimines (PEI) as carriers for siRNA delivery in a CTCL cell model.
• To identify optimal conditions for siRNA delivery and silencing in T-lymphoma cells.
• To discover novel molecular targets for siRNA-mediated growth inhibition in CTCL.

Main Methods:

• Synthesis and characterization of caprylic and linoleic acid substituted 2 kDa PEI (PEI-CA, PEI-LA).
• siRNA delivery and gene silencing assessment in Hut78 and Jurkat T-lymphoma cell lines.
• Optimization of siRNA:carrier ratios and cell centrifugation for enhanced delivery.
• Evaluation of carrier toxicity compared to commercial alternatives.
• Screening of endogenous targets for siRNA-mediated growth inhibition.

Main Results:

• PEI-CA and PEI-LA effectively delivered siRNA to Hut78 and Jurkat cells.
• Green Fluorescent Protein (GFP) silencing was achieved specifically in Hut78 cells.
• High siRNA:carrier ratios and cell centrifugation improved siRNA delivery to Hut78 cells.
• PEI-CA and PEI-LA exhibited lower toxicity than 25 kDa PEI and Lipofectamine® RNAiMAX.
• Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) and cyclin-dependent kinase 18 (CDK18) were identified as viable targets.

Conclusions:

• Lipid-substituted PEI carriers show potential for siRNA delivery in CTCL therapy.
• Optimized delivery conditions and reduced carrier toxicity enhance RNAi efficacy.
• PI3K and CDK18 represent promising molecular targets for controlling CTCL cell proliferation via RNAi.